EGFR and lung carcinoma: The histological subset of lung cancers termed non-small cell lung cancer (NSCLC) has benefitted greatly from the era of precision medicine, where numerous molecular drivers, such as mutant epidermal growth factor receptor (EGFR) or BRaf proto-oncogene (BRAF), can now be identified in a majority of patients and they can be given drugs that directly target those drivers2.